Rocket Lab's Growth Story Is Caught Between a Merger, a Rocket, and a Chart That Won't Cooperate

Rocket Lab posts record Q2 revenue of $234M and $2.36B backlog, but shares are 59% below 52-week high amid Iridium dilution and Neutron schedule pressure.

There are moments when a company's operational narrative and its stock chart tell two entirely different stories. Rocket Lab is living through one of those moments right now — and the gap between the two is getting harder to ignore.

The company just posted a record second-quarter revenue of $234 million, up 62 percent year over year, with a backlog of $2.36 billion. Yet the shares have shed 11 percent since the start of the year and sit a full 59 percent below their 52-week high. That disconnect isn't a quirk of the market; it's the structural reality of a young space company that must keep raising capital to fund the very growth its investors are betting on.

The Iridium Deal Casts a Long Shadow

The most immediate weight on the stock is the planned acquisition of Iridium. The antitrust waiting period has lapsed, registration documents are with the SEC, and FCC applications for the license transfers have been filed. Iridium shareholders are scheduled to vote on September 24.

The deal's structure calls for $27 in cash per Iridium share, plus a variable stock component of Rocket Lab equity. To cover the cash portion, Rocket Lab has inked a new agreement with Deutsche Bank and Wells Fargo that allows for up to $1.94 billion in share issuance through the market. For shareholders, that translates into one word: dilution — and the market is pricing that in well before the vote even happens.

But the Iridium overhang doesn't explain everything. The stock is also trading 18 percent below its 50-day average and 21 percent below its 200-day average, suggesting the downtrend is broader than any single transaction.

Neutron's Timeline Is Getting Tight

Adding to the pressure is the schedule for Neutron, the heavy-lift rocket that's supposed to transform Rocket Lab from a small-satellite launch provider into a serious player in the big-payload game. CEO Peter Beck reaffirmed last week that the launch pad for Neutron is still on track for delivery in the fourth quarter of 2026 — but he also conceded that the window for a first launch by year-end is narrowing.

CFO Adam Spice offered a concrete carrot: if a Neutron test flight succeeds, Rocket Lab could post a positive adjusted operating result in the very next quarter. That would be a milestone for a company that has so far been defined by heavy growth investment. The company also reported progress on pre-flight testing of Neutron's reusable "Hungry Hippo" fairing, a detail that's been read as a positive operational signal.

The Pentagon Pipeline Keeps Flowing

While the Neutron timeline fuels uncertainty, the core business keeps churning out wins. Since the second quarter, management says it has booked more than $1 billion in new orders. The third-quarter guidance of $250 million to $265 million in revenue, with an adjusted EBITDA loss of $17 million to $23 million, makes clear that profitability isn't here yet — but the growth pace hasn't let up.

The defense side of the business is building out quickly. In early August, Rocket Lab secured a $397 million Space Force contract for building, launching, and operating flatellite satellites under the SB-AMTI program. Days later, it joined the Space Force's NITE-STAR IDIQ framework, a $981 million vehicle that qualifies the company for future space test and training infrastructure work. Last week came two more delivery orders totaling $12 million following entry into the Space Data Network Consortium.

There's also the Viasat contract to build a geostationary satellite bus for the Protected Tactical SATCOM-Global program, which runs under a $4 billion overall framework. And Kepler Communications has signed up for a full Neutron mission — the first time Rocket Lab has sold an entire flight rather than a rideshare slot.

Electron Keeps Delivering

The bread-and-butter business remains steady. Last Thursday, Rocket Lab completed its 93rd Electron mission, carrying a QPS-SAR satellite for Japanese customer iQPS. It was the 14th launch of 2026, with nine more iQPS missions booked through 2030. The company also completed its 92nd successful Electron mission in August and unveiled GHOST, a containerized launch system designed to enable orbital and suborbital launches from virtually anywhere on the planet.

Reading the Insider Sales Correctly

For investors scanning recent insider transactions, context matters. Five top executives, including COO Frank Klein, President Marvin Clevenger, and CFO Adam Spice, sold shares worth $5.49 million in late August — but they say the sales were solely to cover tax liabilities from vesting restricted stock units. The executives retained roughly 97.5 percent of their holdings. Klein's separately disclosed sale of 35,558 shares through Morgan Stanley follows the same pattern as his earlier, documented transactions in May and August.

The Real Question for Investors

The stock closed Friday at €55.60, down 4.1 percent on the day, and sits about 18 percent below its 50-day average of €67.82. The technical picture is weak, the merger overhang is real, and the Neutron schedule is tightening. But the operational momentum — record revenue, record backlog, a diversifying defense portfolio — is hard to dismiss.

The answer to whether Rocket Lab is a buy, a hold, or a pass isn't in any single metric. It's in how much patience an investor has while the company simultaneously manages two massive undertakings: integrating Iridium and scaling Neutron. The market is currently pricing in the risks. Whether the rewards eventually outweigh them is a question of timing — and of whether the company can hit the milestones it keeps promising.